



August 17, 2026

Monthly Update

Table of Contents:

1. Status of WUND IPO
2. Status of Pre-IPO for Regenerative Medicine of Europe
3. Washington DC, FreedomFest, and Caribbean Cardiac Conference
- 4. New: Type-1 Diabetes Medical Research Study**
5. New White Paper: Vascular Dementia/Alzheimer's Disease
6. New White Paper: Stroke Recovery
7. Patient Comments
8. Cohort #50 is 100% full

Preface

The July 17, 2026 update was very small and simple, and was meant to "Test the Waters" for the WUND IPO. That July 17 Update went out to the 125,000 readers on the Zhittya email list. I want to thank the many thousands of people who responded to that effort. As the SEC calls it, we have now tested the waters.

Zhittya has made good progress over the last 60 days, and I will address that in this Update.

#1) Status of the WUND IPO

WUND's registration form is at the Securities and Exchange Commission (SEC). I hope WUND will be able to proceed with its initial public share offering in September 2026.

#2) Status of the Pre-IPO for Regenerative Medicine of Europe

I feel good about the status of the WUND IPO, so we are now advancing to our second pre-public marketing company, Regenerative Medicine of Europe. The Pre-IPO placement will fund the cost of the lawyers and auditors, plus give us extra working capital. It is a small offering of 200,000 shares at \$5.00 per share. I believe we have 50% taken after only two weeks, so I hope we will be completed by the end of August. If you have an interest in getting more information, email me at dan333@aol.com.

#3) Washington DC, FreedomFest, and the Caribbean Cardiac Conference

We have had a very busy few weeks.

Washington, DC: Vika and I were in Washington, DC, meeting with important people and advancing our case that if our medicines become approved by the FDA, I believe our medical treatment would lower the cost of health care by hundreds of billions of dollars. It is estimated that \$500 billion is spent every year on diabetes care. If our medicine proves to reverse type 2 diabetes, there is no greater cost savings than 37 million Americans no longer being diabetic.

We met with Vice President JD Vance, Health Secretary Kennedy, Dr. Oz, senators, congressional members, and more. It is nice for me to see that I still have a lot of friends who respect me after having worked on the Nixon, Ford, Reagan, Bush I, Bush II, and Trump campaigns.

I believe our medical science is working. I believe there are tens of millions of people who need our medicines. I believe we can treat millions of people at 20% of the present cost of treatment, save billions of dollars, and make those people healthy. The only barrier is regulatory bureaucracy, which in my opinion is political, not scientific.

The other interesting thing was how many senators, congressional people, staffers, and wealthy donors have these diseases and are excited by what we are doing. There is no easy path to obtain approval, but I think having friends who want to live without a disease and heal their mothers makes our task more possible. I believe our trip was of great value.

FreedomFest, Las Vegas: This was great for us. There were several thousand attendees. Our presentations were well received, and our "Freedom to Try" dinner drew over 350 guests, including the Lt. Governor of the State of Nevada, three US congressional candidates, and numerous other important people. Zhittya's effort to advance a Nevada state constitutional amendment for the "Freedom to Try Medical Innovations" is moving forward.

Caribbean Cardiac Conference, Bahamas: This was also an excellent meeting for us. We are already cleared by the authorities in The Bahamas to treat no-option heart patients. Now we are setting up the doctors, the clinic, and more. We were there for five days, and none of us had any time to go to the beach or even the pool. Our team worked hard to build the ability to treat no-option heart patients in the Bahamas and to get that clinic up and running as soon as possible.

RAADfest is coming September 4, 5, and 6 in Scottsdale, Arizona. RAADfest stands for the Revolution Against Aging and Death. It is the world's largest annual conference and festival focused on longevity and life extension. We have attended this event in the past, and the people who attend are serious about health and life extension. Dr. Jacobs and I will each be presenting data on our medicine. Remember, I know the secret to a long life! The secret is "don't die!" This is what I believe our medicines can do: extend a healthy life. Maybe we will see some of you there.

#4) Zhittya Is Starting a Medical Research Study to Reverse Type-1 Diabetes

Zhittya has been advancing on treating, and I believe reversing, type 2 diabetes. Our data so far is impressive. A friend of mine of over 40 years asked me a few weeks ago whether I believed FGF-1 could reverse type 1 diabetes. I replied that 12 months ago I would have said no! After the data we are seeing from the type 2 patients, I will now say maybe. We have become more interested in type 1 as we have seen the blood work improvement in the type 2 diabetes patients we are

testing. Because of his question, I took the entire Zhittya research team and had them work on the question: Can FGF-1 reverse type-1 diabetes?

In January 2026, we were presented with a Chinese medical research study that attempted to use FGF-1 injected into the abdomen to treat type 2 diabetes. That effort failed. What resulted was data of an amazing increase in pancreas and liver function. In February, we modified our Zhittya Medical Research Study protocol to allow test subjects to volunteer for an additional injection into the belly, to see whether FGF-1 increased their pancreas and liver function. We are now getting that data back. It is a very small sample; however, it is impressive. The only way I believe the increase in insulin yield could be as impressive as what we see is if the beta cells in the pancreas are regenerating and/or rejuvenating.

Our Zhittya research team came back with the following:

1. Yes. FGF-1 can rejuvenate and help generate new beta cells.
2. Yes. FGF-1 can reduce cellular inflammation and enhance beta cell survival.
3. Since type-1 diabetes involves the immune system attacking and killing beta cells, 98% of the published data suggests the new beta cells would also be killed off in an autoimmune response. So, it would be a meaningless effort with no positive outcome.

My wife, Vika Montano, is one of our research people and oversees our medical research studies. She is also much smarter than I am. She disagrees with the 99% of diabetes experts who state that type 1 diabetes is an autoimmune disease. She believes the immune cells could not attack the beta cells if the vascular system were intact. She believes vascular leakage allows immune cells to exit the bloodstream and attack the beta cells. Because of her insistence, we conducted another deep AI dive into the question: does vascular dysfunction (leaky blood vessels) precede the autoimmune attack on the beta cells? A small minority of medical researchers (less than .03%) said yes, and they provided interesting support for that position. We know FGF-1 repairs blood vessels and reduces leakage, and we have now written a concept paper that discusses the potential use of FGF-1 to reverse type-1 diabetes.

If you want a copy of that paper on treating type-1 diabetes, here is a link to it:

Link: zgm.care/t1d

Please note that the medical research paper is dated August 10, 2026. I sent a copy to a man in Texas, and on August 11 he volunteered to be Zhittya's first

type-1 diabetic medical research study patient. It seems he is tired of being a type-1 diabetic, and he likes the idea of helping find a treatment for other type-1 sufferers.

I strongly recommend that if you have a medical curiosity, you read that paper. It is brilliant. Also, is it possible that 99% of the medical experts on type-1 diabetes have been wrong for the last 50 years? I think maybe.

As a personal note, in the 1970s and 1980s I was very active in the Juvenile Diabetes organization in California. I donated, I raised money, and I desperately wanted to stop or defer this horrible disease in children, a disease that alters their lives. I prayed then that we could find a way to reverse type 1 diabetes in children. As we have progressed down this path toward Vika's position that type 1 diabetes is a vascular-dysfunction disease and not an autoimmune disease, I have found myself crying with joy that maybe, finally, my prayers of these last 50 years have been answered. If my prayers from 50 years ago are answered and Zhittya develops a treatment for type 1 diabetes, it means my prayers have come back to me to get the job done. Do it, Dan! My belief in miracles has been strengthened.

The Benefit of Artificial Intelligence (AI)

Type 1 diabetes was first definitively recognized as an autoimmune disease in 1974. In that year, two independent research teams discovered that insulin-dependent diabetes was closely associated with the development of autoantibodies targeting the insulin-producing beta cells in the pancreas. For over 50 years, 99% of medical diabetes experts have embraced the idea that type 1 diabetes is an autoimmune disease. A small group of medical researchers has challenged that belief and published findings that type 1 diabetes may be caused by vascular leakage. Before AI gained the ability to access thousands of medical research papers, many of those studies were buried deep on the shelves of university libraries, and the data you received was always the 99% opinion, never the 1% that disagrees with the majority mantra. Without Vika's deductive logic that immune cells cannot reach the beta cells if the vascularization is healthy, we would never have found the research supporting that minority opinion. With AI, you can ask the question using deductive logic and find out that yes, this idea has some foundation. We all hear the phrase "we need to find something outside the box." Well, 99% of the medical research material is inside the box, and it is next to impossible to find the small percentage outside the box without AI. This effort has opened my mind to what needs to be done with cancer research: search for the

small percentage that is outside the box, not the 99% that has not succeeded in 50 years.

#5) Zhittya's New White Paper on Vascular Dementia and Alzheimer's Disease

Given all we have learned over the last few years, Zhittya has updated its white paper on vascular dementia and Alzheimer's disease.

Roger Craig, the San Francisco 49ers' legendary running back, announced upon his induction into the Pro Football Hall of Fame on August 8, 2026, that he has been diagnosed with vascular dementia. He has given Zhittya permission to announce that he is a test subject in Zhittya's medical research study to reverse vascular dementia. His participation in Zhittya's study has made others aware that there may be a treatment for their vascular dementia. We have updated our white paper because we have had many requests now for information on Zhittya's medical research study for vascular dementia.

To see Roger's statement, you can go to:

https://www.espn.com/nfl/story/_/id/49562214/new-hall-famer-roger-craig-reveals-dementia-diagnosis

To obtain a copy of Zhittya's new white paper on vascular dementia and Alzheimer's disease, you can go to: zgm.care/memory

Worldwide, more than 55 million people live with dementia, according to data from the World Health Organization. Alzheimer's disease is the most common cause and accounts for 60% to 70% of those cases. In the United States, an estimated 7.4 million older adults live with Alzheimer's.

#6) Zhittya's New Stroke Recovery White Paper

An estimated 7 million to 7.8 million adults in the United States live with the effects of a stroke. According to data tracked by the Centers for Disease Control and Prevention, this accounts for about 3.1% of the adult population.

Annual Stroke Numbers

- 795,000 people have a new or recurring stroke each year in the U.S.
- 610,000 of these are first-time attacks.

- 185,000 strokes happen to people who have already had a previous stroke (nearly 1 in 4).
- Every 40 seconds, someone in the United States has a stroke.

Zhittya has been treating several stroke recovery patients over the last four years. We have seen improvements, and we have updated our white paper with more recent medical evidence, such as the fMRI data demonstrating enhanced blood perfusion in the brain after dosing with FGF-1. This is the first demonstration in humans that an agent, such as FGF-1, can increase blood flow in ischemic areas of the brain, and we are very excited!

For a copy of this white paper, go to: zgm.care/stroke

#7) Vika's Patient Comments

Please read Vika's patient comments section below. This covers two months of comments, since in the July Update we only wanted to test the waters. These are real test subjects reporting their own status. There are nine of them, and they reflect reality.

#8) Cohort #50 Is 100% Full

Our partner, Cross-Border Medical Tourism, handles our test subjects. Cross-Border has brought us test subjects from Bolivia, Zambia, the Seychelles, Bangladesh, Dubai, New Zealand, Europe, and more. Our test subjects are treated in groups we call cohorts.

In August 2026, Cross-Border will be treating Cohort #50, and for the first time in four years it is 100% full, with no open slots. It has taken us four years of treating Parkinson's disease patients (over 250), along with stroke, PSP, MSA, autism, multiple sclerosis, and now over 85 type-2 diabetes patients, to have our first cohort with no open slots. People are being deferred to the September and October cohorts. Yes, we must expand our capacity to process more patients. What a wonderful problem.

Please see the Cross-Border section of this Update if you are interested in participating in a medical research study.

Vika's Section

Our Zhittya team has compiled many of our Parkinson's disease patient comments from the last three years of medical research treatments with FGF-1. Here is a link to those patient comments. I hope you find them as interesting as I do.

Zhittya Patient Comments: pd-stories.com

Latest Patient Comments, June 17, 2026 to August 14, 2026

Patient Messages

#1) Hi Vika,

I am writing to let you know that Asha has shown some progress in her mobility. She is able to move around the house without a walker most of the time. She has noticed this since her last FGF-1 dose. It may have been improving slowly, but now it is noticeable.

Thank you,

Baban and Asha (Parkinson's disease)

#2) Hello Vika,

I have completed the booster cycle and I am ready for the next dosing. I am down to one carbidopa/levodopa most days. My hair has gotten thicker. I am more focused.

I love the monthly updates. It is amazing what possibilities you are working on.

With great respect and gratitude,

Pam (Parkinson's disease)

#3) An interesting story:

I had a huge, deep, painful wound on my calf for a few weeks that appeared suddenly. I thought it was a spider bite, because it had a blister that kept coming back. Maybe it was diabetes related, but I have never had diabetic blisters.

After recently taking the Zhittya FGF-1 treatment, I used the remaining residue in the nebulizer and rubbed it onto the wound with a Q-tip. Eight hours later it was

gone. My wife and I could barely see where it had been. I was stunned as I looked and felt for it. Two days later my physical therapist asked me where it was. She could not see any trace of what had been an ugly wound, and there was no scarring whatsoever.

This stuff is a breakthrough. If it can do this to wounds, just imagine the other ways it can help our bodies fight disease.

Arthur (Type-2 Diabetes)

#4) Vika,

First some background. I was diagnosed with Parkinson's disease with orthostatic hypotension. This means that under certain conditions (heat, exercise, a full stomach), my blood pressure drops precipitously when I stand, into the 40s and 50s systolic, and I pass out. Sometimes this results in a trip to the ER because I hit my head on the floor, and it frightens my wife. Finding relief from this symptom was the primary reason I joined the Zhittya medical research study. I was initially dosed in February 2025 in the BVI.

Since then, my wife and I have religiously followed the protocol, but we never observed or felt any positive effects from the FGF-1. No negative effects either, but no positive ones. Then, after dosing with the seventh of ten FGF-1 vials on June 8, I noticed my first positive effect. It was so dramatic that I can remember the day, the time, and the task I was doing. A couple of hours after dosing, I was driving to the pharmacy, and my mind was as sharp and clear as it had been before this disease took over my life. It had not been that clear for a couple of years. The next day I felt more energetic with better balance. By the second or third day the effects began to fade, but I had hope that they would return after the next dosing and last longer. They did.

The next time, they lasted almost a week. Now I am down to my last vial, the brain fog is mostly gone all the time, and I have more energy almost every day. I have gone from using a cane for balance, to walkers and a wheelchair. Currently I only occasionally use a cane, and I hope that becomes a thing of the past too.

The point I would like to make is this. It was about 17 months from my initial dosing in the BVI to the day I realized positive effects. I had almost given up hope that FGF-1 would work for me. In one of your newsletters, somebody wrote that we do not contract Parkinson's disease overnight, and healing does not happen overnight either.

In a follow-up on August 12, he added: my energy is at about 75% of what it was, up from a low of about 30% this past winter and spring. My tremors are not as positive. They are a little worse. I am hoping to see improvement there in the future.

Best wishes to you, your family, and the Zhittya team.

Respectfully,

Richard (Parkinson's disease)

#5) Hey Vika,

I want to thank you for your care and concern, and for providing FGF-1. Here is an update on my last dosing cycle.

I walk every day for a mile around my block in beautiful Alabama. When I first started in March, I could only walk a short distance before I would freeze and sometimes fall. I wear knee pads so I do not skin my knees when I fall forward, and it would take me a while to get started walking again. I stopped at every turn and every incline.

Now I walk the whole mile without stopping, most of the time. I am standing up taller. And best of all, I am not feeling fatigued. I feel good all day and I am sleeping better. Nesy and I are getting out and going places. I still have trouble going through some doorways and turning around sometimes.

I am so thankful for FGF-1.

Stephen (Parkinson's disease)

#6) Vika,

I used it, and a week after use I have the usual clarity of mind and restoration of short-term memory. Amazing.

My wife is using the vaporizer and her results are quite noticeable. She is much calmer, a bit more clearheaded, and shows considerably less stress-related behavior. I will keep you updated.

Greg

#7) RE: Lab Rat 90 Day Parkinson Research Study Report

Hello Vika,

The 90-day window for the Parkinson research study for Lab Rat Phil is now completed. I thought everyone may be interested in my findings. I know they sure were a surprise to me. Overall, the following improvements from receiving the FGF-1 are:

Bowel functionality improvement. This happened very soon after the initial treatment with FGF-1...

Parkinson medication reduction. Presently I am up to a 30% reduction in my Parkinson medication. This is beyond possible for any conventional Parkinson's treatments. This, if nothing else, provides evidence that FGF-1 is activating dopamine production in my body.

Mental alertness and wakefulness improvement. Definitely experiencing a more active and focused brain with less drowsiness. In addition, my overall attitude has become very positive. I have regained much of my motivation and drive to accomplish tasks.

Blood pressure reduction. This was somewhat of a shocker... I was taking a very low dose of blood pressure medication. I actually bottomed out with my blood pressure and had to stop taking [it]. My blood pressure now is better than it was when I was dosed...

Significant reduction in Parkinson "OFF" time. I am experiencing more "UP" time during the day with fewer Parkinson symptoms and requirement for short naps.

Most of the improvements from the FGF-1 have occurred in the past few weeks... I have a theory; I call it the 3 D's of FGF-1 activity with our body's dopamine-producing neurons: *Dormant*... dopamine-producing neurons that are dormant get reactivated immediately, which explains the quick resolution of some Parkinson symptoms... *Dying*... dopamine-producing neurons that are dormant but starting to die are healed (resurrected), which explains the response I am experiencing in the past few weeks. *Dead*... FGF-1 needs to stimulate angiogenesis for cleanup of cellular garbage, provide increased tissue oxygenation and stimulate regrowth of dopamine-producing neurons.

Finally, my current symptoms and conditions showing no improvements yet: dystonia (right foot), leg muscle weakness and pain, foot and leg neuropathy, sense of taste, sense of smell.

My next treatment of FGF-1 is scheduled for September 1st. I am really looking forward to this. I totally believe that it will accelerate my healing and complete elimination of both my Parkinson medications and my symptoms...

Kind regards,

Phil (Parkinson's disease)

#9) Dear Vika,

I want to share my progress on my dosing of the FGF-1 molecule late January, 2026.

3-16-2026: My chart shows Type 2 diabetes in remission. A1C 6.3.

6-23-2026: Assessment in remission. Patient is off all meds.

Most recent A1C 6.4 (the higher end of the pre-diabetic range). That only means one thing... I'M NOT TYPE 2 DIABETIC!

I was able to reduce Metoprolol in half as well as 2000 mg of Metformin a day. I'm enjoying the lack of intestinal problems the Metformin causes...

Keep up the great work, and I'm telling everyone I know about Zhittya and the magic molecule.

John (type-2 diabetes)

#10) PD symptom improvements related to my Zhittya Genesis Medicine medical study of the fibroblast protein FGF-1.

1st improvement: Significant reduced off time effect of low back pain and pressure at belt level and elimination of muscle spasms at the level of hip joints... I have thus concluded that the off period effect was being brought on earlier by too high a level of carbidopa levodopa. I have been at 16 pills per day, taken in 4 dose sessions separated by 4 or 4-1/2 hour spacings. In considering reducing my carbidopa levodopa usage, I have considered that Zhittya has run over 240 PD patients through their study over the past 4 years and found that FGF-1 patients can progress faster if they can trim down the carbidopa levodopa usage. FGF-1 works to increase the blood perfusion, reducing buildup of cellular trash and healthier endothelial cells, and it's best to naturally restart dopamine neuron function rather than over medicate...

Action taken to test reduced carbidopa levodopa total dose: Starting around June 18, 2026 I reduced the carbidopa levodopa total dose to 12 tablets per day, for approximately 18 days, and found a significant reduction in the low back pain, which I had just come to recognize as an off period pain indicator. This was done with a dose pill count order of 3 at about 7:30 am, 3 at about noon, 3 at about 4 pm and 3 at about 8 pm.

I have found this to be beneficial, but out of caution, on 7/7/2026 I adjusted to testing at only a slightly lower reduction level of 14 tablets per day, for another 18 day test... No particular advantage or disadvantage was observed. Currently, as of 7/24/2026, I have started a test sequence at a 13 pill count order per day... Eventually I will retest again at the 12 tablet level before considering going on to an 11 tablet per day test level.

2nd improvement: Around the 1st of June I noticed that I couldn't recall the last time that I had a tremor in my left hand wrist... Neither type of these two tremors have been at a severe problem level, and could often be mentally controlled. The wrist tremor now seems to be resolved. I now look forward to other improvements in my PD symptoms.

Dick (Parkinson's disease)

Cross-Border Medical Tourism

Cross-Border Medical Tourism services are for people who want to be considered for Zhittya's future clinical trials or current medical research studies. Cross-Border is now arranging medical tourism to treat Parkinson's disease patients, stroke recovery, type-2 diabetes patients, and vascular dementia, and soon, I hope, chronic pain and type-1 diabetes.

Cross-Border is working on filling the Las Vegas medical research studies (intranasal FGF-1 for Parkinson's disease and type-2 diabetes, and more) on the following dates:

- Cohort #50: August 24 – 26, 2026
- Cohort #51: September 28 – 30, 2026
- Cohort #52: October 26 – 28, 2026

To be considered for a cohort, please contact Sam Cross at Cross-Border Medical:

Email: Sam.crossbordermedical@gmail.com Phone: 714 393-8605

If you are also interested in participating in a functional MRI brain scan study at Washington University in St. Louis, please let Sam know. There are a finite number of imaging slots. These studies will examine brain blood flow before and after FGF-1 treatment.

Upcoming Events

RAADfest, September 4, 5, and 6, 2026 Talking Stick Resort, Scottsdale, Arizona
Speakers: Dr. Jack Jacobs and Dan Montano

Conclusion by Dan Montano:

I must be careful what I say, so that I do not offend the SEC, now that we are in the final stages of the WUND IPO.

Life is an interesting journey for all of us. Every month has its problems, its rewards, its frustrations, and its joys. I have been on this journey to develop FGF-1 as a medical treatment for 28 years. I have no doubt FGF-1 can grow new blood vessels in the heart to treat the number one cause of death in the world: heart disease. I have no doubt FGF-1 can enhance blood flow in the brain to treat Parkinson's disease, stroke, dementia, Alzheimer's disease, multiple sclerosis, traumatic brain injuries, autism, and more. I believe, but still do not know for sure, that FGF-1 can rejuvenate glucose-sensing neurons in the brain to reverse type-2 diabetes and maybe also treat type-1 diabetes. Now it has been revealed that FGF-1 could rejuvenate nerve cells and perhaps reduce pain for maybe a billion people worldwide.

Every month we have become aware of new medical applications for FGF-1. Discovery means you do not know something. As the Zhittya team investigated, can FGF-1 treat type-1 diabetes, my heart was broken, when all the data stated FGF-1's ability to regenerate and rejuvenate beta cells were meaningless since the autoimmune system would kill the new beta cells. Vika insisted that this belief lacked common sense, since the vascularization tubes (blood vessels) protect beta cells from many things in our blood stream that can harm other cells. Vika strongly insisted that the immune cells were only allowed to reach the beta cells if there is vascular leakage. In an estimated over 100,000 medical research papers on diabetes, only about 30 papers advanced that the immune attack happens if the blood vessels are leaky. We do not know if (1) that is accurate, (2) if FGF-1 can

heal those blood vessels and (3) if FGF-1 regenerates/rejuvenates the beta cells that it will enhance the life of those people. We know it is possible. Since FGF-1 has had a very safe profile, Zhittya looks forward to finding those answers.

Many people lecture me on the way Zhittya is advancing its medicine and doing Medical Research Studies is not the normal way done by Big Pharma and others. With a 95% failure rate, 20 years to get a medicine approved and at a cost of billions of dollars, why would any rational person with common sense follow a traditional pathway that does not work. Yes, we are doing things differently. Over the last 20 years, I estimate that \$5 billion dollars have been raised by organizations to find a treatment for Parkinson's disease, and I have not seen them show improvement in one patient yet. Zhittya has treated over 250 patients and please read their comments - many are getting better, not worse. Billions have gone into the war against cancer, heart disease, dementia, Alzheimer's disease, diabetes, ALS and more with little to show for it.

Maybe like 99% of the diabetic experts, they are saying what they heard and learned 50 years ago and have never challenged it. The great thing about being poor in East Los Angeles, with a Mexican father and a Scots-Irish mother is you belong to no societal clubs or accepted respectable establishment groups. All you have is a lot of challenges and a willingness to fight. If the odds are 99% against you with a 1% chance of success, then you have the story of my life. When Vika refused to accept what our own people had accepted, the traditional 99% establishment position that type-1 diabetes was an autoimmune disease, and said they were wrong, I knew why I loved her! We fight not because we want fame or fortune (I have had both, and it did not make me happy); it is because millions of children's lives are damaged by this horrible disease, and maybe we have a 1% chance to change that. Given the odds are 99% against us being right and 1% we enhance the lives of millions of children, you know I am in that fight. That is better odds than in 1948, a poor Mexican kid in East LA advising presidents, prime ministers, and chancellors. When you are raised in a tough neighborhood, there is a saying: "It is not the size of the dog in the fight that wins; it is the size of the fight in the dog." Zhittya may not be a big dog in this fight, but we fight like a champion dog!

Zhittya's management is task driven to get RESULTS!

I believe we have a better pathway than the traditional medicine development pathway. Zhittya's task is to get results, and I believe we are on a better pathway, and I have bet everything I have on that!

As always, I thank you for your support and your guidance.

I am blessed, and I pray that you are also blessed.

God bless you and thank you all.

Dan Montano

CEO, Zhittya Genesis Medicine

8683 W. Sahara Ave.,

Suite 280

Las Vegas, NV 89117, USA

702-802-8373

zgm.care